Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.

@article{Sauna2007SilentPS,
  title={Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer.},
  author={Zuben E. Sauna and Chava Kimchi-Sarfaty and Suresh V Ambudkar and Michael M. Gottesman},
  journal={Cancer research},
  year={2007},
  volume={67 20},
  pages={9609-12}
}
Polymorphisms in the human genome contribute to wide variations in how individuals respond to medications, either by changing the pharmacokinetics of drugs or by altering the cellular response to therapeutic agents. The goal of the emerging discipline of pharmacogenomics is to personalize therapy based on an individual's genotype. Due to the relatively large frequency of single-nucleotide polymorphisms (SNP) in the human genome, synonymous SNPs are often disregarded in many pharmacogenomic… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.
118 Citations
29 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 118 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Similar Papers

Loading similar papers…